Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.31 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30689540 | 0.85 | ALDH1A1 (0.35) | BCHEALDH1A1CYP2D6MAPK1METAP2 | |
| SCHEMBL25435703 | 0.84 | ALDH1A1 (0.36) | BCHEALDH1A1CYP2D6MAPK1METAP2 | |
| SCHEMBL19492149 | 0.84 | ALDH1A1 (0.36) | BCHEALDH1A1CYP2D6MAPK1METAP2 | |
| SCHEMBL20394018 | 0.81 | ALDH1A1 (0.35) | BCHEALDH1A1CYP2D6MAPK1METAP2 | |
| SCHEMBL20272046 | 0.81 | ALDH1A1 (0.35) | BCHEALDH1A1CYP2D6MAPK1METAP2 | |
| SCHEMBL20394084 | 0.81 | TK1 (0.36) | BCHECYP2D6LMNA | |
| SCHEMBL20756448 | 0.79 | ALDH1A1 (0.37) | BCHEALDH1A1CYP2D6MAPK1METAP2 | |
| SCHEMBL23152976 | 0.79 | ALDH1A1 (0.37) | BCHEALDH1A1CYP2D6MAPK1METAP2 | |
| SCHEMBL23153000 | 0.79 | BCHE (0.33) | BCHEALDH1A1CYP2D6MAPK1METAP2 | |
| SCHEMBL19101763 | 0.78 | LMNA (0.39) | BCHEALDH1A1CYP2D6MAPK1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3351548-B1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2025-08-20 | — | — | EP | disclosed |
| EP-3974436-A1 | CROSSLINKED NUCLEIC ACID GUNA METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2022-03-30 | — | — | EP | disclosed |
| US-10961269-B2 | Bridged nucleic acid GuNA, method for producing same, and intermediate compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-03-30 | — | — | US | disclosed |
| US-20180251488-A1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-09-06 | — | — | US | disclosed |
| EP-3351548-A1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961269-B2 | Bridged nucleic acid GuNA, method for producing same, and intermediate compound | POLRMT, POLM, NSUN2 | BCHE 4041/4885ALDH1A1 808/4885CYP2D6 3468/4885 |
| US-20180251488-A1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | NSUN2, RNMT, POLRMT | BCHE 4402/4885ALDH1A1 1062/4885CYP2D6 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.